In this issue:
Clinical outcomes of escalation vs early intensive DMT for MS
Global burden of MS
Comparison of two high doses of oral methylprednisolone for MS
Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of RRMS
Long-term effectiveness of interferonbeta and glatiramer acetate in MS
Disease courses in familial vs sporadic MS
Dimethyl fumarate in patients with RRMS from East Asia
Dietary and lifestyle factors in MS progression
Quantitative susceptibility mapping identifies inflammation in a subset of chronic MS lesions
Predicting clinical progression in MS
Please login below to download this issue (PDF)